Stay updated on ACTT: Remdesivir for Severe COVID-19 Clinical Trial
Sign up to get notified when there's something new on the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page.

Latest updates to the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedUpdate includes a new operating status notice and version bump to v3.2.0; removal of the previous v3.1.0 note indicates version update.SummaryDifference1%

- Check28 days agoChange DetectedUpdated page version from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.0%

- Check35 days agoChange DetectedCore content on drug safety and related topics has been removed, reducing important information about drug safety, counterfeit drugs, pharmaceutical preparations, and substandard drugs.SummaryDifference0.1%

- Check42 days agoChange DetectedUpdated to revision v3.0.2, replacing v3.0.1; the Back to Top link was removed. No substantive changes to core content like pricing or availability are indicated.SummaryDifference0.1%

- Check49 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.1%

- Check56 days agoChange DetectedThe webpage has undergone significant updates, including the addition of detailed drug information for Remdesivir and the inclusion of various locations and names associated with COVID-19 treatment. Notably, the facility names and specific locations have been revised to reflect current data.SummaryDifference8%

Stay in the know with updates to ACTT: Remdesivir for Severe COVID-19 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page.